In a single-institution phase I dose-escalation and -expansion trial reported as a letter in Nature Medicine, Shah et al found that treatment with tandem bispecific anti-CD20/anti-CD19 4-1BB–CD3ζ lentiviral chimeric antigen receptor (CAR) T cells produced high response rates in adult patients with relapsed B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia.
In a retrospective analysis reported in JCO Oncology Practice, Durani et al found that the use of surveillance imaging in patients with diffuse large B-cell lymphoma (DLBCL) decreased following publication of the American Society of Hematology (ASH) Choosing Wisely recommendations to limit such imaging in aggressive lymphoma.
In an analysis of two German Hodgkin Study Group trials reported in the Journal of Clinical Oncology, Bröckelmann et al found that second-line treatment with conventional polychemotherapy resulted in similar second progression–free survival durations vs high-dose chemotherapy plus autologous stem cell transplantation after relapse in patients with early-stage, favorable, classical Hodgkin lymphoma.
Results from an early-phase clinical trial investigating the histone deacetylase (HDAC) inhibitor vorinostat in combination with the mTOR inhibitors sirolimus or everolimus found the combination therapies showed activity in heavily pretreated patients with relapsed or refractory Hodgkin lymphoma. The study by Janku et al was published in Clinical Cancer Research.
Researchers have identified molecular and cellular characteristics of anti-CD19 chimeric antigen receptor (CAR) T-cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and develop side effects. The research team also found that early changes in circulating tumor DNA 1 week after administration of CAR T-cell therapy may be predictive of treatment response. These findings were published by Deng et al in Nature Medicine.